Strategic Partnerships Leverage Mycovia's existing licensing and collaboration history, including the 2019 licensing of oteseconazole to Jiangsu Hengrui and the 2019 Gedeon Richter collaboration, to identify new regional or manufacturing partnerships that expand geographic reach, accelerate regulatory approvals, or co-develop next-generation oral antifungals.

Product Expansion Target opportunities around expanding VIVJOA’s indications or portfolio with additional fungal infections and resistant strains, while monitoring de-risked development programs for oral antifungal inhibitors that could broaden the company’s disease area footprint beyond RVVC.

U.S. Market Momentum Capitalize on U.S. market launch momentum for VIVJOA since July 2022 and the FDA designations received to position supplementary sales efforts, payer negotiations, and brand awareness campaigns that could drive higher adoption and payer coverage in women’s health and infectious disease segments.

Global Licensing Identify license and distribution opportunities in international markets where oteseconazole could be co-developed or co-commercialized, leveraging Mycovia’s existing oncology and infectious disease expertise to penetrate regions with limited access to azole antifungals.

Clinical and R&D Synergy Engage in discussions around strategic research collaborations for novel oral fungal inhibitors and multi-drug resistant pathogens, aligning business development with Mycovia’s pipeline potential to create long-term growth through shared development costs and commercialization rights.